Using gain and loss of function approaches in CD34+ cells from healthy donors and MDS cases, we demonstrate the role of this TF in promoting inefficient erythroid differentiation, indicating that DDIT3 may be a therapeutic target for patients with the disease. This evidence concerns the gene DDIT3 and myelodysplastic syndrome.